...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Clovis' Rubracra
6
Oct 03, 2018 01:02PM

masila - I am not a science person and have very little knowledge on the science behind Zenith. With that in mind it seems to me that ZEN3694 was never designed to do a job on its own but to be administered as part of a combination that would elicit a better, longer experience than the current standard of care drugs on their own. I believe in past presentations it has been said that 3694 has been tested with over 30 existing cancer drugs. On average those drugs work about 60% better in combination with 3694. My question then becomes; will these PARP's being developed now, work better in combination with 3694 before we say anything about being to late to the party?

tada

6
Oct 05, 2018 11:45AM
7
Oct 05, 2018 12:12PM
Share
New Message
Please login to post a reply